THE DEAL, AT A GLANCE
From the announcementSRTD Biotech
01What it doesWe are especially grateful to Mérieux Equity Partners for their vision, conviction, and unwavering support in building SRTD into an integrated RNA therapeutics company…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Mérieux Equity Partners, Lilly Ventures, HTGF, Anobis AssetFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedSRTD Biotech raised Series A, announced 2026-11-09From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersSRTD Biotech's financing places capital into an integrated RNA therapeutics company, but the recorded deal terms conflict: the verified deal field reports $0M at Series…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
SRTD Biotech · Financing Record
Explore source-linked visual explanations for SRTD Biotech. Unsupported claims are withheld while source review continues.
Record 15666 · Recorded date: 2026-11-09
What it does
SRTD Biotech develops selectively expressed RNA (seRNA) therapies that activate only in diseased cells, for oncology, autoimmune and fibrosis indications.
Source: srtd-biotech.com ↗